Physician profile
Rashmi Gupta
NPI 1932181989
$5,421.09
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $848 · 2021: $1,433 · 2022: $1,142 · 2023: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,937.11 | 2019-2023 | Briviact, Fintepla, Nayzilam |
| Neurelis, INC. | $480.60 | 2020-2023 | Valtoco |
| Aquestive Therapeutics, INC. | $441.06 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $428.06 | 2019-2023 | Jornay Pm |
| Corium, LLC | $333.08 | 2022-2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $318.87 | 2019-2021 | |
| Greenwich Biosciences, INC. | $245.17 | 2019-2021 | |
| Tris Pharma INC | $230.52 | 2020-2023 | Dyanavel Xr |
| Eisai INC. | $228.77 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $167.57 | 2020-2023 | Qelbree |
| Adlon Therapeutics L.P. | $138.00 | 2020-2021 | |
| Neos Therapeutics, LP | $118.19 | 2019 | |
| Jazz Pharmaceuticals INC. | $103.78 | 2022-2023 | Epidiolex |
| Sk Life Science, INC. | $60.91 | 2020-2022 | |
| Zogenix INC. | $42.34 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $41.46 | 2023 | Aptiom |
| Takeda Pharmaceuticals U.S.A., INC. | $29.37 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $19.83 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $13.67 | 2020 | |
| Abbvie INC. | $12.17 | 2021 | |
| Allergan, INC. | $11.07 | 2020 | |
| Shire North American Group INC | $10.84 | 2019 | |
| Travere Therapeutics, INC. | $8.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.